• Single-molecule detections at point-of-care: is this a dream?

    Research news

    Single-molecule detections at point-of-care: is this a dream?

    Join Luisa Torsi as she discusses single-molecule detections at point-of-care during her webinar.

    • Webinar date: 13 February
    • Time: 7-8 PM GMT
    • Presented by: Luisa Torsi
    • Sign up HERE>>

    Imagine a future where diseases can be detected at their earliest stages, even before symptoms appear.

    This is no longer a dream but a revolutionary step forward in healthcare. And it's made possible by the groundbreaking SiMoT (Single-Molecule-with-a-large-Transistor) bioelectronic platform.

    Join us for this insightful webinar to discover how this technology is set to transform diagnostics.

    A new era in early disease detection

    Detecting diseases in asymptomatic individuals is a game-changer. It enables timely interventions and significantly improving patient outcomes.

    The SiMoT platform aligns with the World Health Organization’s benchmarks for point-of-care testing (POCT), offering unparalleled sensitivity and specificity in a portable, cost-effective format.

    As part of the SiMBiT project, SiMoT is capable of detecting both protein and DNA single markers in just 0.1 mL of biological fluid.

    This level of precision makes it an ideal tool for early disease screening, even in individuals showing no symptoms.

    Unmatched diagnostic performance

    SiMoT offers diagnostic accuracy on par with molecular tests, achieving an impressive 96-99% sensitivity and specificity.

    This exceptional performance was demonstrated in a pre-clinical trial for pancreatic cancer. No false negatives were reported among more than 70 patients.

    Such results highlight the potential of SiMoT to revolutionize early disease detection.

    Real-world applications and clinical trials

    The SiMoT platform is undergoing rigorous evaluation in an in-vivo diagnostic clinical trial involving 1,500 assays of blood and urine samples from oncology patients.

    This trial aims to advance the technology from TRL5 to TRL7, bringing it closer to widespread clinical adoption.

    Additionally, the SiMBiT project’s development of a 96-bioelectronic sensor array for multiplexed detection has been validated in clinical trials for early cancer screening, further demonstrating its potential.

    Key learnings from the webinar

    By attending this webinar, you will:

    • Discover early detection capabilities
    • Explore diagnostic precision
    • Gain SiMBiT project insights
    • Shape the future of healthcare.

    Why attend?

    This webinar is your chance to learn from one of the leading minds in the field, Luisa Torsi.

    You will gain insights into a technology that promises to redefine diagnostic capabilities.

    Whether you’re a healthcare professional, researcher, or simply interested in cutting-edge innovations, this session is not to be missed.

    Sign up now

    Don’t miss this opportunity to be part of a transformative discussion on the future of healthcare.

    Secure your spot NOW>>


    Digital Edition

    Lab Asia 32.2 April

    April 2025

    Chromatography Articles - Effects of small deviations in flow rate on GPC/SEC results Mass Spectrometry & Spectroscopy Articles - Waiting for the present to catch up to the future: A bette...

    View all digital editions

    Events

    Medtec Japan 2025

    Apr 09 2025 Tokyo, Japan

    FORUMESURE

    Apr 22 2025 Hammamet, Tunisia

    Korea Lab 2025

    Apr 22 2025 Kintex, South Korea

    Analytica Anacon India & IndiaLabExpo

    Apr 23 2025 Mumbai, India

    Analitika Expo 2024

    Apr 23 2025 Moscow, Russia

    View all events

    Great Job...
    The latest issue will be with you shortly
    Sign up to Labmate for FREE.
    Register and get the eBulletin, a Monthly email packed with the latest Laboratory products, news and services. Join us and get the latest Laboratory information first.